Abstract
The COVID-19 pandemic is still a burden to the global health care system, affecting its capacity to maintain essential health services. Even though specific treatment and prevention options are available, the SARS-CoV-2 virus keeps accumulating mutations over time and challenging the efficiency of vaccines, causing new outbreaks and increasing hospitalisation. Early studies suggest that mortality from COVID-19 is increased by age and certain comorbidities. Thus, the goal of this study was to analyse patients hospitalised with COVID-19 pneumonia in terms of age, sex, and comorbidities. Additionally, the influence of treatment with Remdesivir and vaccination on hospitalisation duration and disease outcome was also analysed. The results showed that lethal disease outcome is mainly increased by age and gender, where older and male patients are at a higher risk. There were less deaths in patients with primary arterial hypertension. Other comorbidities did not have a statistically significant influence on disease outcome. Among those who survived, a higher number of patients had been treated with Remdesivir. Vaccination did not have an impact on disease outcome. It could be concluded that older and male patients are the risk group with a worse disease outcome. Treatment with Remdesivir shows a positive effect on disease outcome, although further detailed analysis is necessary.